PI Industries Limited Q2 FY27 revenue falls 9% as margin drops

PI Industries Limited reported consolidated revenue of ₹1,701.8 crore for Q2 FY27, down 9% year-on-year, while EBITDA margin declined to 14% from 29% as agchem export weakness, pricing pressure and higher input costs affected profitability. The Board approved the unaudited results for the quarter ended September 30, 2026, on November 4, 2026.

What did PI Industries report for Q2 FY27?

PI Industries reported consolidated Q2 FY27 revenue of ₹1,701.8 crore, compared with ₹1,872.3 crore in Q2 FY26. EBITDA declined 57% year-on-year to ₹236.2 crore from ₹543.4 crore, while profit after tax fell 70% to ₹122.2 crore from ₹409.3 crore. The reported numbers are unaudited and were included in the company’s earnings presentation.

For the first half of FY27, consolidated revenue was ₹3,404.1 crore, down 10% year-on-year from ₹3,772.8 crore. EBITDA for the half year stood at ₹605.5 crore, down 43%, and profit after tax was ₹366.4 crore, down 55%. Standalone Q2 revenue from operations was ₹1,533.5 crore, while standalone profit before tax was ₹275.2 crore.

Why did PI Industries’ profitability decline?

PI Industries’ profitability declined as its agchem export business faced weaker demand, genericisation and pricing pressure. Agchem exports fell about 18% year-on-year during the quarter. The company also cited cost escalation that was not fully passed through to customers, contributing to the reduction in gross margin to 49% from 57% a year earlier.

Input costs increased by 5%, according to the presentation, adding to pressure on the cost base. These factors led to a sharper fall in EBITDA than in revenue. The Q2 EBITDA margin of 14% was less than half the 29% margin reported in the corresponding quarter of FY26, showing the effect of export-market conditions on operating leverage.

The company did not provide an earnings-call transcript with management guidance in the material provided. Its presentation, however, identified export demand, pricing and genericisation as the key operational factors behind the quarterly performance.

Which businesses supported PI Industries during the quarter?

PI Industries’ domestic revenue grew 19% year-on-year in Q2 FY27, partly offsetting the decline in exports. The domestic business was supported by biological products, where revenue rose more than 45%. The company linked the growth to product launches and an expanding market presence.

The biologicals business also recorded global growth of 250%. PI Industries cited expansion across the United States, Brazil and Mexico as contributors to this increase. Health Sciences revenue grew 20% during the quarter, including the start of commercial GMP manufacturing of Galidesivir API.

The contrast between domestic and export performance is important for the business mix. Domestic growth and health sciences expansion supplied support during a weak export quarter, but they were not sufficient to neutralise the decline in the larger agchem export operations and the associated margin pressure.

How is PI Industries managing cash and investment?

PI Industries reduced its trade working-capital cycle by 18 days in H1 FY27, releasing ₹298.1 crore of cash. The company reported a surplus cash position of ₹3,573.7 crore net of debt. These figures indicate that cash conversion improved despite the lower revenue and profit reported for the period.

Capital expenditure reached ₹567.4 crore in H1 FY27. The investment programme is linked to the company’s development pipeline and production capabilities. PI Industries has said it expects more than five new products to be commercialised during FY27, although the presentation does not quantify the financial contribution expected from these launches.

A recent product development milestone was the October 29 unveiling of Pioxaniliprole, described by the company as India’s first indigenously discovered insecticide molecule. PI Industries’ roadmap indicates an India launch within FY27, followed by overseas filings in subsequent years.

What does the Q2 result mean for investors and the agrochemical sector?

The Q2 result shows that PI Industries remains exposed to the global agrochemical cycle, particularly export demand and pricing conditions. Revenue fell 9%, but EBITDA and profit fell materially faster because lower export realisations and higher input costs compressed margins. Investors tracking the company will therefore need to assess both revenue recovery and the pace of margin normalisation.

At the same time, the quarter highlighted diversification within the portfolio. Domestic revenue, biologicals and health sciences registered growth, while the shortened working-capital cycle strengthened liquidity. The balance between these expanding businesses and the export-facing agchem franchise will remain relevant to the company’s reported financial performance.

Conclusion

PI Industries reported a weaker Q2 FY27, with consolidated revenue of ₹1,701.8 crore falling 9% year-on-year and EBITDA margin declining to 14%. Export weakness, genericisation, pricing pressure and input-cost inflation drove the contraction, while domestic revenue, biologicals and health sciences provided growth in selected areas.

The next disclosures to watch are progress on the planned commercialisation of more than five products in FY27, the domestic launch of Pioxaniliprole, and changes in agchem export demand and pricing. Investors may also monitor whether the 18-day improvement in working capital and the reported net cash surplus continue as capital expenditure proceeds.